Compare Novartis AG (NVS) vs Under Armour Inc Class A (UA) Price & Performance

Novartis AGTrade

Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Novartis AG vs Under Armour Inc Class A — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Under Armour Inc Class A trades at $7.18 (market cap $3.07B). The key difference: Novartis AG is far larger — about 94.5× Under Armour Inc Class A's market cap, and Novartis AG pays a 3.17% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.

	NVS	UA
Market Cap	$290.25B	$3.07B
Sector	Health	Consumer Cyclical
52-Week High	$168.62	$7.88
52-Week Low	$113.50	$3.96
Enterprise Value	$330.27B	$4.70B
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.

Under Armour Inc Class A

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 5 days agoBullish View details →

Under Armour to report Q1 fiscal 2027 results on August 7, 2026, with a follow-up earnings call.PRNewsWire · 4 days agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.